Skip to main content
Premium Trial:

Request an Annual Quote

Bioinn to Distribute Courtagen's NGS Tests in Taiwan

NEW YORK (GenomeWeb) – Courtagen Life Sciences today announced a deal with Bioinn Molecular Diagnosis to provide Courtagen's clinical next-generation sequencing tests for neurological and metabolic disorders in Taiwan.

Courtagen's tests provide information on the genetic causes of disorders including epilepsy, intellectual disability, autism spectrum disorders, and mitochondrial dysfunction.

"The distribution agreement with Bioinn is another important step in the execution of our global strategy to support the increasing demand of our products," Courtagen President Brendan McKernan said in a statement. Financial and other terms of the deal were not disclosed.

Last month, Couragen and Sciencewerke signed an agreement for the international distribution of Courtagen's tests.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.